Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
SAN DIEGO, May 12 /PRNewswire/ --
- All Patients in Cohort 3 Demonstrated Improvement in T-Cell Responses Further Supporting the Therapeutic Potential of HspE7
Nventa Biopharmaceuticals Corporation…